NO316644B1 - Lactobacillusstammer av human opprinnelse, blandinger samt anvendelse derav - Google Patents
Lactobacillusstammer av human opprinnelse, blandinger samt anvendelse derav Download PDFInfo
- Publication number
- NO316644B1 NO316644B1 NO19964966A NO964966A NO316644B1 NO 316644 B1 NO316644 B1 NO 316644B1 NO 19964966 A NO19964966 A NO 19964966A NO 964966 A NO964966 A NO 964966A NO 316644 B1 NO316644 B1 NO 316644B1
- Authority
- NO
- Norway
- Prior art keywords
- strains
- cncm
- lactobacillus
- intestinal
- lactobacilli
- Prior art date
Links
- 241000186660 Lactobacillus Species 0.000 title claims abstract description 50
- 229940039696 lactobacillus Drugs 0.000 title claims abstract description 28
- 239000000203 mixture Substances 0.000 title claims description 25
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims description 27
- 230000000968 intestinal effect Effects 0.000 claims description 13
- 238000011282 treatment Methods 0.000 claims description 13
- 230000001575 pathological effect Effects 0.000 claims description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 7
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000011321 prophylaxis Methods 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 241000894007 species Species 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 235000013365 dairy product Nutrition 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000012876 carrier material Substances 0.000 claims description 2
- 230000000295 complement effect Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 20
- 244000052769 pathogen Species 0.000 description 14
- 241000894006 Bacteria Species 0.000 description 13
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 13
- 210000000941 bile Anatomy 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000002955 isolation Methods 0.000 description 9
- 239000002609 medium Substances 0.000 description 8
- 230000001580 bacterial effect Effects 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 5
- 210000003608 fece Anatomy 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 210000002919 epithelial cell Anatomy 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000004347 intestinal mucosa Anatomy 0.000 description 4
- 244000000074 intestinal pathogen Species 0.000 description 4
- 235000013336 milk Nutrition 0.000 description 4
- 239000008267 milk Substances 0.000 description 4
- 210000004080 milk Anatomy 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108010062877 Bacteriocins Proteins 0.000 description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 235000013958 Lactobacillus casei Nutrition 0.000 description 2
- 101100396933 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) imm2 gene Proteins 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000000688 enterotoxigenic effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000010544 Bacterial Toxin Neutralization Effects 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000016938 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000194031 Enterococcus faecium Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 244000005709 gut microbiome Species 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 229940017800 lactobacillus casei Drugs 0.000 description 1
- 108010042648 lactocin Proteins 0.000 description 1
- 230000028744 lysogeny Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Dairy Products (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITMI941073A IT1269838B (it) | 1994-05-26 | 1994-05-26 | Ceppi di lattobacilli di origine umana e loro usi |
| ITMI941773A IT1274733B (it) | 1994-08-25 | 1994-08-25 | Ceppo del genere lactobacillus di origine umana e suoi usi |
| PCT/EP1995/001886 WO1995033046A1 (en) | 1994-05-26 | 1995-05-18 | Lactobacillus strains of human origin, their compositions and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO964966D0 NO964966D0 (no) | 1996-11-22 |
| NO964966L NO964966L (no) | 1997-01-23 |
| NO316644B1 true NO316644B1 (no) | 2004-03-22 |
Family
ID=26331139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19964966A NO316644B1 (no) | 1994-05-26 | 1996-11-22 | Lactobacillusstammer av human opprinnelse, blandinger samt anvendelse derav |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US5709857A (de) |
| EP (1) | EP0760848B1 (de) |
| JP (1) | JP3653277B2 (de) |
| CN (1) | CN1094972C (de) |
| AT (1) | ATE163042T1 (de) |
| AU (1) | AU686389B2 (de) |
| BR (1) | BR9507752A (de) |
| CA (1) | CA2191213C (de) |
| DE (2) | DE760848T1 (de) |
| DK (1) | DK0760848T3 (de) |
| ES (1) | ES2099056T3 (de) |
| FI (1) | FI119059B (de) |
| GR (2) | GR970300016T1 (de) |
| HU (1) | HU220190B (de) |
| MX (1) | MX9605807A (de) |
| NO (1) | NO316644B1 (de) |
| NZ (1) | NZ287420A (de) |
| WO (1) | WO1995033046A1 (de) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPN175495A0 (en) * | 1995-03-14 | 1995-04-13 | University Of New England, The | Method and composition for the prevention of the over production of acid |
| AUPN698495A0 (en) * | 1995-12-06 | 1996-01-04 | Pharma Pacific Pty Ltd | Improved therapeutic formulation and method |
| IT1289159B1 (it) | 1997-01-08 | 1998-09-29 | Yurta S R L | Composizioni farmaceutiche e alimentari a base di batteri del genere acetobacter |
| IT1289984B1 (it) * | 1997-02-27 | 1998-10-19 | Proge Farm Srl | Ceppi di lattobacilli utili nel trattamento di disfunzioni del sistema gastrointestinale |
| IT1299070B1 (it) * | 1998-04-10 | 2000-02-07 | Proge Farm Srl | Ceppi di lattobacilli capaci di inibire e/o avere azione microbicida nei confronti di microorganismi patogeni e metodo di induzione e |
| US7202219B1 (en) * | 1998-02-24 | 2007-04-10 | Md Foods Amba | Use of D-tagatose as a prebiotic food component |
| DE69802260T2 (de) | 1998-04-30 | 2002-07-04 | Renata Maria Anna Cavaliere Vesely | Pharmazeutische Zusammensetzungen enthaltend Lactobacillus brevis und Lactobacillus salivarius zur Behandlung von Vaginainfektionen |
| US7029702B2 (en) * | 1998-07-07 | 2006-04-18 | Ritter Natural Sciences Llc | Method for increasing lactose tolerance in mammals exhibiting lactose intolerance |
| US6080401A (en) * | 1998-11-19 | 2000-06-27 | Reddy; Malireddy S. | Herbal and pharmaceutical drugs enhanced with probiotics |
| HUP0200374A2 (en) | 1999-03-11 | 2002-06-29 | Nestle Sa | Lactobacillus strains capable of preventing diarrhoea caused by pathogenic bacteria and rotaviruses |
| EP1034788A1 (de) * | 1999-03-11 | 2000-09-13 | Société des Produits Nestlé S.A. | Milchsäure Bakterienstämme zur Verhinderung von Diarrhöe |
| EP1034787A1 (de) * | 1999-03-11 | 2000-09-13 | Société des Produits Nestlé S.A. | Lactobacillus Stämme die gegen pathogenische Bacteria veranlassende Diarrhöe schutzen |
| US20040105848A1 (en) * | 1999-04-30 | 2004-06-03 | Natarajan Ranganathan | Enteric dialysis compositions and methods |
| US20040166101A1 (en) * | 1999-09-22 | 2004-08-26 | Bojrab Gregory G. | Enchanced composition for treatment of gastrointestinal disorders and hyperlipidemia |
| US6696057B1 (en) | 1999-09-22 | 2004-02-24 | Lacpro Industries, Inc. | Composition and method for treatment of gastrointestinal disorders and hyperlipidemia |
| US6641808B1 (en) * | 1999-09-22 | 2003-11-04 | Lacpro Industries, Llc | Composition for treatment of obesity |
| AU2001233529A1 (en) | 2000-02-10 | 2001-08-20 | Andrew W. Bruce | Probiotic therapy for newborns |
| EP1303256B1 (de) | 2000-06-09 | 2009-01-07 | Baylor College of Medicine | Kombination von antimikrobiellen wirkstoffen und bakterieller interferenz zum überziehen medizinischer vorrichtungen |
| AUPQ899700A0 (en) | 2000-07-25 | 2000-08-17 | Borody, Thomas Julius | Probiotic recolonisation therapy |
| US7214370B2 (en) | 2000-12-18 | 2007-05-08 | Probiohealth, Llc | Prebiotic and preservative uses of oil-emulsified probiotic encapsulations |
| IL156490A0 (en) | 2000-12-18 | 2004-01-04 | Probiohealth | Probiotic compounds derived from lactobacillus casei strain ke01 |
| US7060687B2 (en) * | 2001-02-07 | 2006-06-13 | Genmont Biotechnology Co. | Live vaccines for allergy treatment |
| NO318426B1 (no) * | 2001-10-02 | 2005-04-18 | Neurozym Biotech As | Et materiale for a senke konsentrasjonen av patogene tarmpeptider |
| US8147821B2 (en) | 2002-02-21 | 2012-04-03 | Grain Processing Corporation | Method for drying biomaterials |
| EP1485463B1 (de) | 2002-03-21 | 2008-09-24 | Bifodan A/S | Lactobacillus-stämme |
| WO2006012536A2 (en) * | 2004-07-22 | 2006-02-02 | Ritter Andrew J | Methods and compositions for treating lactose intolerance |
| CA2547144C (en) | 2005-05-16 | 2010-02-02 | Grain Processing Corporation | Method for drying spent filter media |
| CN101273736B (zh) * | 2007-03-28 | 2012-08-08 | 北京弗蒙特生物技术有限公司 | 一种在常温下保持高活菌数的发酵乳的制备方法 |
| EP2016834B1 (de) * | 2007-07-13 | 2009-11-04 | Unilever N.V. | Nahrungsmittel mit Bakterien und Sorbitan-Fettsäure |
| US20090041727A1 (en) * | 2007-08-08 | 2009-02-12 | Conjugon, Inc. | Compositions and Methods for Microbe Storage and Delivery |
| US20110223248A1 (en) * | 2007-12-12 | 2011-09-15 | Ritter Pharmaceuticals, Inc. | Methods and compositions for treating lactose intolerance |
| EP2293802A4 (de) * | 2008-06-25 | 2011-11-09 | Ritter Pharmaceuticals Inc | Lactosezusammensetzungen mit reduziertem lactosegehalt |
| KR101003149B1 (ko) * | 2008-10-31 | 2010-12-22 | 전남대학교산학협력단 | 병변 치료용 박테리아 기반의 마이크로로봇 |
| EP2206506A1 (de) | 2008-12-18 | 2010-07-14 | Bracco Imaging S.p.A | Probiotische Formulierungen |
| US8785160B2 (en) | 2009-02-24 | 2014-07-22 | Ritter Pharmaceuticals, Inc. | Prebiotic formulations and methods of use |
| KR20110124780A (ko) | 2009-02-24 | 2011-11-17 | 리터 파마슈티컬즈 인코오포레이티드 | 프리바이오틱 제제 및 사용 방법 |
| EP2248908A1 (de) | 2009-05-05 | 2010-11-10 | Eurolactis Group S.A. | Aus Eselsmilch isolierte probiotische Mikroorganismen |
| WO2011009848A2 (en) | 2009-07-20 | 2011-01-27 | Bracco Spa | Therapeutic use of probiotics |
| EP3311825A1 (de) | 2010-08-04 | 2018-04-25 | Thomas Julius Borody | Zusammensetzungen zur darmfloratransplantation und verfahren zur herstellung davon und verwendung davon |
| EP2683390B1 (de) | 2011-03-09 | 2017-05-03 | Regents Of The University Of Minnesota | Zusammensetzungen und verfahren zur transplantation von biozönose des kolon |
| US9719144B2 (en) | 2012-05-25 | 2017-08-01 | Arizona Board Of Regents | Microbiome markers and therapies for autism spectrum disorders |
| AU2013322644B2 (en) * | 2012-09-25 | 2019-05-16 | Aquilon Cyl S.L. | Probiotic and prebiotic compositions |
| AU2016262615C1 (en) | 2015-05-14 | 2021-06-10 | Finch Therapeutics Holdings Llc | Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them |
| CN114366759A (zh) | 2015-05-22 | 2022-04-19 | 亚利桑那大学董事会 | 用于治疗自闭症谱系障碍及相关症状的方法 |
| US20170360848A1 (en) | 2016-06-15 | 2017-12-21 | Arizona Board Of Regents On Behalf Of Arizona State University | Methods for treating autism spectrum disorder and associated symptoms |
| US10849936B2 (en) | 2016-07-01 | 2020-12-01 | Regents Of The University Of Minnesota | Compositions and methods for C. difficile treatment |
| US20180036352A1 (en) | 2016-08-03 | 2018-02-08 | Crestovo Holdings Llc | Methods for treating ulcerative colitis |
| WO2018071537A1 (en) | 2016-10-11 | 2018-04-19 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| US11213549B2 (en) | 2016-10-11 | 2022-01-04 | Finch Therapeutics Holdings Llc | Compositions and method for treating primary sclerosing cholangitis and related disorders |
| US10092601B2 (en) | 2016-10-11 | 2018-10-09 | Crestovo Holdings Llc | Compositions and methods for treating multiple sclerosis and related disorders |
| CN110831606A (zh) | 2017-04-05 | 2020-02-21 | 克雷斯顿沃控股公司 | 治疗帕金森氏病(pd)和相关疾病的组合物和方法 |
| US11040073B2 (en) | 2017-04-05 | 2021-06-22 | Finch Therapeutics Holdings Llc | Compositions and methods for treating diverticulitis and related disorders |
| WO2018218159A1 (en) | 2017-05-26 | 2018-11-29 | Crestovo Holdings Llc | Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods for making and using same |
| WO2019032573A1 (en) | 2017-08-07 | 2019-02-14 | Finch Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR MAINTAINING AND RESTORING A HEALTHY INTESTINAL BARRIER |
| US11166990B2 (en) | 2018-07-13 | 2021-11-09 | Finch Therapeutics Holdings Llc | Methods and compositions for treating ulcerative colitis |
| JP2022514145A (ja) | 2018-09-27 | 2022-02-10 | フィンチ セラピューティクス ホールディングス エルエルシー | てんかんおよび関連する障害を治療するための組成物および方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4839281A (en) * | 1985-04-17 | 1989-06-13 | New England Medical Center Hospitals, Inc. | Lactobacillus strains and methods of selection |
| US4946791A (en) * | 1986-10-02 | 1990-08-07 | Bio Techniques Laboratories, Inc. | Novel strain of Lactobacillus acidophilus |
| US5179020A (en) * | 1991-08-19 | 1993-01-12 | Bio Techniques Laboratories, Inc. | Antibiotic resistant strain of lactobacillus acidophilus |
| EP0577904B1 (de) * | 1992-07-06 | 1997-05-14 | Societe Des Produits Nestle S.A. | Milchbakterien |
-
1995
- 1995-05-18 DE DE0760848T patent/DE760848T1/de active Pending
- 1995-05-18 MX MX9605807A patent/MX9605807A/es unknown
- 1995-05-18 CA CA002191213A patent/CA2191213C/en not_active Expired - Fee Related
- 1995-05-18 HU HU9603251A patent/HU220190B/hu not_active IP Right Cessation
- 1995-05-18 NZ NZ287420A patent/NZ287420A/en not_active IP Right Cessation
- 1995-05-18 AU AU26139/95A patent/AU686389B2/en not_active Ceased
- 1995-05-18 BR BR9507752A patent/BR9507752A/pt not_active IP Right Cessation
- 1995-05-18 JP JP50024096A patent/JP3653277B2/ja not_active Expired - Fee Related
- 1995-05-18 WO PCT/EP1995/001886 patent/WO1995033046A1/en active IP Right Grant
- 1995-05-18 EP EP95920830A patent/EP0760848B1/de not_active Expired - Lifetime
- 1995-05-18 DE DE69501591T patent/DE69501591T2/de not_active Expired - Lifetime
- 1995-05-18 DK DK95920830T patent/DK0760848T3/da active
- 1995-05-18 AT AT95920830T patent/ATE163042T1/de active
- 1995-05-18 ES ES95920830T patent/ES2099056T3/es not_active Expired - Lifetime
- 1995-05-18 CN CN95193239A patent/CN1094972C/zh not_active Expired - Fee Related
-
1996
- 1996-06-17 US US08/664,447 patent/US5709857A/en not_active Expired - Lifetime
- 1996-11-22 NO NO19964966A patent/NO316644B1/no not_active IP Right Cessation
- 1996-11-25 FI FI964681A patent/FI119059B/fi not_active IP Right Cessation
-
1997
- 1997-05-30 GR GR970300016T patent/GR970300016T1/el unknown
-
1998
- 1998-04-30 GR GR980400957T patent/GR3026758T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US5709857A (en) | 1998-01-20 |
| GR970300016T1 (en) | 1997-05-31 |
| FI119059B (fi) | 2008-07-15 |
| DK0760848T3 (da) | 1998-09-23 |
| JPH10500577A (ja) | 1998-01-20 |
| NO964966L (no) | 1997-01-23 |
| ATE163042T1 (de) | 1998-02-15 |
| NO964966D0 (no) | 1996-11-22 |
| MX9605807A (es) | 1997-12-31 |
| DE69501591T2 (de) | 1998-06-10 |
| FI964681A (fi) | 1997-01-08 |
| BR9507752A (pt) | 1997-10-07 |
| JP3653277B2 (ja) | 2005-05-25 |
| AU686389B2 (en) | 1998-02-05 |
| WO1995033046A1 (en) | 1995-12-07 |
| EP0760848A1 (de) | 1997-03-12 |
| CA2191213C (en) | 2008-03-18 |
| HUT75555A (en) | 1997-05-28 |
| ES2099056T3 (es) | 1998-04-01 |
| NZ287420A (en) | 1997-12-19 |
| HU220190B (hu) | 2001-11-28 |
| GR3026758T3 (en) | 1998-07-31 |
| ES2099056T1 (es) | 1997-05-16 |
| AU2613995A (en) | 1995-12-21 |
| CA2191213A1 (en) | 1995-12-07 |
| DE760848T1 (de) | 1997-08-28 |
| DE69501591D1 (de) | 1998-03-12 |
| FI964681A0 (fi) | 1996-11-25 |
| CN1154715A (zh) | 1997-07-16 |
| EP0760848B1 (de) | 1998-02-04 |
| CN1094972C (zh) | 2002-11-27 |
| HU9603251D0 (en) | 1997-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO316644B1 (no) | Lactobacillusstammer av human opprinnelse, blandinger samt anvendelse derav | |
| Maldonado et al. | Lactic acid bacteria isolated from young calves–characterization and potential as probiotics | |
| Victor et al. | Probiotic properties of lactobacilli strains isolated from raw cow milk in the western highlands of Cameroon | |
| EP1005353B1 (de) | Lactobacillus casei rhamnosus-haltige pharmazeutische formulierung | |
| Sreekumar et al. | Immediate effect of Lactobacillus acidophilus on the intestinal flora and fecal enzymes of rats and the in vitro inhibition of Escherichia coli in coculture | |
| US20110236359A1 (en) | Antimicrobial Activity of Bacteriocin-Producing Lactic Acid Bacteria | |
| Tinrat et al. | Isolation and characterization of Lactobacillus salivarius MTC 1026 as a potential probiotic | |
| ITRM20110475A1 (it) | Ceppi di batteri lattici e/o bifido batteri, opzionalmente addizionati di n-acetilcisteina e/o lisozima microincapsulato gastroprotetto, aventi attivita' di inibizione/riduzione della crescita di differenti biotipi di e.coli, incluso e.coli o157:h7 e | |
| Miyamoto et al. | Lactobacillus flora in the cloaca and vagina of hens and its inhibitory activity against Salmonella enteritidis in vitro | |
| Strompfová et al. | Lactobacilli and enterococci—potential probiotics for dogs | |
| Pato et al. | Antibiotic resistance and antibacterial activity of dadih originated Lactobacillus casei subsp. casei R-68 against food borne pathogens | |
| US20130011374A1 (en) | Growth inhibition of microorganisms by lactic acid bacteria | |
| Kazuń et al. | In vitro study of Lactobacillus plantarum properties as a potential probiotic strain and an alternative method to antibiotic treatment of fish | |
| Murphy | In vivo assessment of potential probiotic Lactobacillus salivarius strains: evaluation of their establishment, persistence, and localisation in the murine gastrointestinal tract | |
| ES2296635T3 (es) | Bifidobacteria capaz de prevenir la diarrea. | |
| KR100240687B1 (ko) | 락토바실러스 애시도필러스 ky 2104 및 그 용도 | |
| Kheadr | Impact of acid and oxgall on antibiotic susceptibility of probiotic Lactobacilli | |
| Gomes et al. | Comparison of antagonistic ability against enteropathogens by G+ and G− anaerobic dominant components of human fecal microbiota | |
| DebMandal et al. | Detection of intestinal colonization of probiotic Lactobacillus rhamnosus by stool culture in modified selective media | |
| US20030077255A1 (en) | Compositions of bacteria and alpha-lactalbumin and uses thereof | |
| Tsai et al. | Toxicity evaluation for an Enterococcus faecium strain TM39 in vitro and in vivo | |
| KR100720025B1 (ko) | 프로바이오틱 유산균 및 이를 포함하는 조성물 | |
| Mandal et al. | Therapeutic potential of Lactobacillus ingluviei ADK10, a newly established probiotic organism against acetaminophen induced uremic rats | |
| RU2364623C2 (ru) | Бактериальный штамм бифидобактерий - продуцент фолиевой кислоты (варианты), его применения и пробиотическая композиция | |
| Ali et al. | Isolation, identification and characterization of lactic acid bacteria from traditional yogurt |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |